Judd Moul, MD, FACS

Financial relationships

  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Sanofi-Aventis
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Dendreon
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Bayer
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Blue Earth Diagnostics
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Genomic Health
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Ferring
    Mitigation strategy: 
    Divest
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Exosome Dx
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Consultant or Advisor (Oncology)
    Ineligible company: 
    Tolmar
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Meeting Participant or Lecturer (Oncology)
    Ineligible company: 
    Astellas
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022
  • Attribution: 
    Self
    Type of financial relationship: 
    Scientific Study or Trial (Oncology)
    Ineligible company: 
    Pfizer
    Mitigation strategy: 
    Peer review
    Date reviewed: 
    09/20/2022

Pages

Return to 2022 AUA Annual Meeting Highlights: Prostate Cancer